A Multi-center, Open-label, 2-treatment, Single-sequence Clinical Study to Evaluate the Effects of a Single 200 mg Subcutaneous Injection of Sarilumab on the Pharmacokinetics of a Single 40 mg Oral Dose of Simvastatin, With Optional 1-year Extension of Open Label Treatment of Sarilumab, in Patients With Rheumatoid Arthritis

Trial Profile

A Multi-center, Open-label, 2-treatment, Single-sequence Clinical Study to Evaluate the Effects of a Single 200 mg Subcutaneous Injection of Sarilumab on the Pharmacokinetics of a Single 40 mg Oral Dose of Simvastatin, With Optional 1-year Extension of Open Label Treatment of Sarilumab, in Patients With Rheumatoid Arthritis

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Oct 2016

At a glance

  • Drugs Sarilumab (Primary) ; Simvastatin
  • Indications Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Sanofi
  • Most Recent Events

    • 08 Oct 2016 Results published in the Clinical Pharmacokinetics
    • 06 Apr 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record
    • 07 Oct 2014 Planned End Date changed from 1 Oct 2015 to 1 Mar 2016 as reported by ClinicalTrial.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top